Truist Financial
PCVX icon

Truist Financial’s Vaxcyte PCVX Stock Holding History

Truist Financial’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,167
Closed -$341K – 2626
2024
Q4 		$341K Sell
4,167
-862
-17% -$85.6K ﹤0.01% 2087
2024
Q3 		$575K Sell
5,029
-1,191
-19% -$107K ﹤0.01% 1787
2024
Q2 		$470K Sell
6,220
-674
-10% -$45.9K ﹤0.01% 2010
2024
Q1 		$471K Sell
6,894
-1,911
-22% -$132K ﹤0.01% 1995
2023
Q4 		$553K Buy
8,805
+991
+13% +$51.5K ﹤0.01% 1908
2023
Q3 		$398K Sell
7,814
-177
-2% -$8.73K ﹤0.01% 2045
2023
Q2 		$399K Buy
+7,991
New +$379K ﹤0.01% 2092

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Truist Financial's PCVX Position: Q1 2025 in Review

Truist Financial sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 4,167 shares — an estimated $341K sold.

Truist Financial first reported a position in PCVX in Q2 2023 and held it in 7 quarters. The position peaked at $575K in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Truist Financial reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Truist Financial sold 4,167 Vaxcyte shares in Q1 2025, an estimated $341K.
  • Truist Financial first reported a position in Vaxcyte in Q2 2023 and held it in 7 quarters.
  • Truist Financial's Vaxcyte position peaked at $575K in Q3 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Truist Financial's 13F filing for Q1 2025, filed 29 Apr 2025.